Insights From Chief Scientific Officer Stefan Randl At CPHI Frankfurt 2025

The pharmaceutical industry faces growing pressure to bring new therapies to patients faster while maintaining the highest standards of quality, safety, and regulatory compliance. Rising development costs, increasing pricing pressures, and patent expirations are driving organizations to find new ways to accelerate timelines across the drug development lifecycle.

Achieving greater speed requires more than streamlined clinical trials. As development programs move faster, chemistry, manufacturing, and controls (CMC) activities are becoming a critical determinant of success. Scientific excellence, flexible manufacturing capacity, and integrated development strategies can help minimize delays, improve technology transfer, and support smoother progression from early development through commercialization.

Emerging technologies are also reshaping the landscape. Artificial intelligence, digital twins, advanced planning tools, and data-driven manufacturing approaches have the potential to improve process development, optimize production, and strengthen collaboration across pharmaceutical companies, manufacturing partners, and regulators. Discover how innovation, operational agility, and connected data ecosystems are helping accelerate the path from discovery to market.